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Background: Quitting smokers gain weight. This deters some from trying to stop smoking and may explain the
increased incidence of type 2 diabetes after cessation. Dieting when stopping smoking may be counterproductive.
Hunger increases cravings for smoking and tackling two behaviours together may undermine quitting success.
A meta-analysis of randomized controlled trials (RCTs) showed individualized dietary support may prevent weight
gain, although there is insufficient evidence whether it undermines smoking cessation. Commercial weight
management providers (CWMPs), such as Slimming World, provide individualized dietary support for National
Health Service (NHS) patients; however, there is no evidence that they can prevent cessation-related weight gain.
Our objective is to determine whether attending Slimming World from quit date, through referral from NHS Stop
Smoking Services, is more effective than usual care at preventing cessation-related weight gain.
Methods: This RCT will examine the effectiveness of usual cessation support plus referral to Slimming World
compared to usual cessation support alone. Healthy weight, overweight and obese adult smokers attending Stop
Smoking Services will be included. The primary outcome is weight change in quitters 12 weeks post-randomization.
Multivariable linear regression analysis will compare weight change between trial arms and adjust for known
predictors of cessation-related weight gain.
We will recruit 320 participants, with 160 participants in each arm. An alpha error rate of 5% and 90% power will
detect a 2 kg (SD = 2.5) difference in weight gain at 12 weeks, assuming 20% remain abstinent by then.
Discussion: This trial will establish whether referral to the 12-week Slimming World programme plus usual care is
an effective intervention to prevent cessation-related weight gain. If so, we will seek to establish whether weight
control comes at the expense of a successful quit attempt in a further non-inferiority trial.
Positive results from both these trials would provide a potential solution to cessation-related weight gain, which
could be rolled out across England within Stop Smoking Services to better meet the needs of 0.75 million smokers
stopping with NHS support every year.
Trial registration: Current Controlled Trials ISRCTN65705512
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Weight gain is a well known consequence of smoking
cessation [1,2]. It may deter smokers from attempting to
quit [3] and offsets some advantages of giving up smoking.
Smoking cessation-related weight gain partly explains the
finding that the incidence of type 2 diabetes is increased
by up to 73% in the years after cessation [4-6] and there is
a 30% increased risk of hypertension [7] compared to
continuing smoking. Quitters who gain weight have
less improvement in lung function than those who
avoid weight gain [8].
An ideal intervention to prevent weight gain would
begin at the time of quitting, because weight gain is
most rapid initially and then the rate of gain slows
[9,10]. Qualitative findings suggest that, in the overweight
population, at least, waiting until a quit attempt is
established before addressing weight is unacceptable [11].
However, preventing weight gain early in cessation is
controversial. The main reason quit attempts fail is due
to quitters succumbing to their cravings to smoke. Evidence
suggests that hunger increases urges to smoke [12,13] and
people who gain most weight are more likely to succeed in
quitting smoking [14]. This suggests that avoiding hunger
and ameliorating cigarette cravings with food may enhance
smoking abstinence and this has become standard advice
on how to quit, with healthy food choices often advocated.
We investigated the effectiveness of different interven-
tions to prevent weight gain during cessation in a recent
Cochrane review update [15]. General dietary education
to reduce energy intake through eating a low fat, healthy
diet and increasing exercise did not prevent weight gain
compared to standard smoking cessation behavioral
support. Furthermore, there was a statistically significant
reduction in abstinence at 12 months (Table 1). However,
an individually tailored plan to reduce energy intake
and increase exercise, with regular monitoring and
adaptation of individual goals, reduced weight gain at
6 and 12 months without a statistically significant reduc-
tion in abstinence rates (Table 1), although the sample size
is too small to be conclusive.
Commercial weight management providers (CWMPs)
offer this type of individually tailored dietary and exercise
plan. They have already been shown to be an effective way
for people to achieve successful weight loss through referral
from NHS primary care [16]. Therefore referral to a
CWMP on prescription from the National Health ServiceTable 1 Effects of dietary interventions on weight change and
Intervention compared to standard smoking
cessation
Mean difference in w
End of treatment
General lifestyle and calorie reducing dietary advice −0.04 (−0.57, 0.50)
Individually tailored dietary and lifestyle advice −1.11 (−1.93, −0.29)
CI, confidence interval; RR, risk ratio.(NHS) Stop Smoking Services may be an effective way to
prevent smoking-related weight gain without a detrimental
effect on quitting success. The first step to investigating this
is to run a trial to assess whether this is an effective way to
prevent weight gain during smoking cessation.
We will use the results of such a trial to inform a larger
trial powered to investigate non-inferiority on smoking
cessation rates. This will assess whether weight control
comes at the expense of a successful quit attempt. This trial
would require over 1,100 participants and is premature
without first showing that the intervention can reduce
weight gain, which is what we propose here. We will seek
further funding for the larger trial to investigate effects on
abstinence if the intervention reduces weight gain.
Methods
Design
This is an open label, phase II, randomized controlled trial
(RCT) to compare standard stop smoking behavioral
support with an intervention that will, in addition to pro-
viding standard stop smoking support, include personalized
weight management support, provided by Slimming World.
This is an open label trial, so blinding patients and
smoking cessation advisors to allocation to intervention or
control is impossible. The primary outcome is objectively
measured weight and therefore the scope for bias is
limited. Stop smoking advisors, who will weigh partici-
pants, will not provide the weight control support and are
unlikely to have a vested interest in interpreting weight
change favorably. In addition, they will be required to
follow a protocol that specifies outdoor coats and
shoes only are removed before weighing.
Setting
We propose recruiting participants from NHS commis-
sioned Stop Smoking Services within Bristol and
North Somerset in the first instance. Participating
services located within pharmacies, general practices
and community centers will display an A3 poster
advertising the trial.
Participants
Inclusion criteria
 Daily smokers with expired CO >10 ppm.
 Aged 18 years or over.abstinence during smoking cessation
eight change (kg (95% CI)) Abstinence (RR (95% CI))
At 12 months End of treatment At 12 months
−0.21 (−2.28, 1.86) 0.90 (0.76, 1.06) 0.66 (0.48, 0.90)
−2.58 (−5.11, −0.05) 1.11 (0.84, 1.46) 0.74 (0.39, 1.43)
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m2. We included participants with an ideal BMI, as
well as those who are overweight in the trial. This is
because we are not only seeking to help people who
are overweight to manage their weight, but also to
enable those who are a healthy weight to prevent
the weight gain that is associated with smoking
cessation. Without engaging in weight management
strategies to counteract the physiological and
behavioral responses to smoking cessation, 85% of
people who quit smoking will gain weight, regardless
of their starting BMI [17].
 Willing to be randomized to either the control or
intervention arm, and willing and able to comply
with the intervention and all study procedures.
 Able to understand and consent to study
procedures, assessed at first appointment with the
stop smoking advisor.
Exclusion criteria
 Pregnant smokers.
 BMI <23 kg/m2. Mortality has been shown to be
lowest in people with a 22 >BMI <25 [18], therefore
preventing weight gain in those with lower BMIs
may not lead to health gain.
 Any medical condition in which weight loss would
be contraindicated, for example current course of
chemotherapy.
 Currently losing weight, intentionally or
unintentionally.
 Participating in any other intervention trial.
Withdrawal criteria
Participant decision to withdraw from treatment and
follow-up
Participants may choose to withdraw from treatment
and/or follow-up at any time. Failure to attend treatment
visits will not be considered as withdrawal from the
whole trial, and these participants will still be contacted
for follow-up appointments unless they have requested
otherwise. We expect that participants who actively request
to withdraw from the trial and no longer be contacted will
be fewer than 5% of participants, and as such we will not
replace these individuals.
Research team decision to withdraw
The intervention is based on the principles of healthy
eating and we do not expect any adverse effects. Standard
practice within the intervention is to monitor weight and
provide feedback, and therefore an unhealthy rate of
weight loss is unlikely to occur for long without correction.
In the event that a participant develops a condition in
which dietary energy restriction is ill-advised, for exampleembarking on a course of chemotherapy, they will be
withdrawn from treatment. Data up to the time of
withdrawal from treatment will be used unless the
participant requests otherwise. Before beginning the
trial, participants will have to consent to notifying the
research team of such a change in medical history
which is detailed on the consent form. We will ask
the participant’s general practitioner to notify the research
team of such changes in medical history.
Randomization
A randomization sequence will be generated using
computer software. Stratified randomization by stop
smoking advisor with blocking within each stratum will
be used to ensure balance. The blocks will be randomly
ordered blocks of 2, 4 and 6. Participants will be
randomized 1:1 to usual care or Slimming World with
usual care after they have consented to take part in the
study. Stop smoking advisors, who are unaware of the
randomization sequence, will open sealed, numbered,
opaque envelopes in turn, after consent and initial
procedures to determine allocation. Online or telephone
randomization is not practical in many smoking cessation
clinics because they do not have access to computers and
operate outside of normal office hours.
Interventions and comparisons
Trial treatment providers
Trained NHS stop smoking advisors will provide
participants with standard smoking cessation support,
which is intended to be identical in both arms of the
trial. Weight control support will be provided by
trained weight management counselors employed by
Slimming World. Slimming World is a CWMP which
follows the National Institute for Health and Care
Excellence (NICE) criteria for clinical practice. It is
commissioned by the NHS to provide a weight loss
service to patients.
Provision of standard NHS stop smoking support
All participants will receive standard NHS stop smoking
support. This will be the withdrawal oriented behavioral
support provided by NHS Stop Smoking Services, which
increases the chance of a successful quit attempt by
four-fold [19]. This consists of weekly behavioral support
typically for 2 weeks before and until 4 weeks after quit
day, focusing on key behavioral change techniques,
and nicotine replacement, varenicline or bupropion are
prescribed to relieve withdrawal symptoms.
Standard stop smoking treatment consists of six
sessions [20]. These are pre-booked when participants
contact the Stop Smoking Service. Our trial will be
nested within this usual practice as described below and
shown in Figure 1.
Week 0: quit week
Recruitment of those who want to 
take part.
-Check eligibility 
-Obtain consent 
-Take baseline measures 
-
Reveal random allocation 
Week-1: pre-quit week
Participant Information Sheet 
given to those attending
Usual Care Appointment made at  
CWMP
Weeks +1 to +3: 
Stop smoking support
Weeks +1 to +3: 
Stop smoking support
Continued attendance at 
CWMP until week +12
Week+4: 
End of stop smoking support 
4 week abstinence measure 
Weight measured 
EQ-5D
Week +12, +26: 
Follow-up 
CO & weight measured 
EQ-5D 
Week +12, +26: 
Follow-up 
CO & weight measured 
EQ-5D 
Week+4: 
End of stop smoking support 
4 week abstinence measure 
Weight measured 
EQ-5D
Figure 1 Flow diagram showing flow of participants through
trial and main procedures. −, weeks before quitting; 0, quit week;
+, weeks after quitting.
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Session 1: pre-quit session (week −1 prior to quit day)
During the first visit, as is usual practice, all smokers will
set a quit date for 1 to 2 weeks in advance and their
supply of medication to help them quit will be discussed.
Smokers will be given the participant information sheet
explaining the trial, providing potential participants
enough time for consideration between this and the next
visit. The information sheet states the opportunity to
take part is entirely optional and that choosing not to
participate will have no bearing on receiving usual stop
smoking support.
Session 2: quit week (week 0)
At the second visit, smokers are usually ready to quit
the next day and they will be either already taking
varenicline or bupropion, or provided with nicotine
replacement therapy at this visit.
Smokers will be asked whether they would like to
participate in the trial. Before doing so, the stop smoking
advisor will go through the trial information to make
sure they have understood what is involved; for example
they have to agree to attend Slimming World ifrandomized to it and be prepared not to go to a CWMP
of their own volition if they are not randomized to it.
Those who decline to take part will be invited to give
a reason. Those who agree to take part in the trial will
provide written evidence of consent and will then be
screened for eligibility by the stop smoking advisor.
Baseline measures will be taken and they will be
randomized into either usual care or Slimming
World with usual care. The stop smoking advisor
will provide those who are randomized to the intervention
with a referral to Slimming World. This is to be taken and
used at the local Slimming World group to coincide as
near as possible with their quit date.
Baseline measures include a questionnaire asking for each
participant’s age, gender, socioeconomic status, ethnicity,
religion, daily cigarette consumption, and Fagerström test
for nicotine dependence (FTND) score as usually measured
by Stop Smoking Services. They will also be asked to
complete the EQ-5D (EuroQol, Rotterdam, Netherlands)
measure of health status and report whether they suffer
from type 2 diabetes mellitus.
Sessions 3 to 5: weeks 1 to 3 post-quit (week +1, +2, +3)
The next three sessions will provide behavioral support
for quitting in both the intervention and usual care group.
The intervention group will also attend Slimming World.
Session 6: week post-quit (week +4)
This is typically the last visit to the Stop Smoking Service
and when 4-week abstinence will be assessed. Weight will
be measured and the EQ-5D will be completed by all
participants at this visit.
Session 7: 12-week follow-up (week +12)
This corresponds with the end of weight management
treatment. Weight and smoking abstinence will be
measured. This session is important for determining the
sample size needed for the non-inferiority trial which, as is
standard in stop smoking trials [21], will require a 6-month
follow-up to assess long-term smoking abstinence.
Session 8: 26-week follow-up (+26)
If data from 12-week follow-up shows a difference in
mean weight, we will include a 26-week follow-up.
The numbers of individuals who will return at this
point will be recorded, and weight and smoking abstinence
will be measured.
Intervention
CWMPs are available ‘on prescription’ through general
practices and provide 12 weeks of free membership of
the group-based weight management class. There are
three main providers offering services to the NHS:
Rosemary Conley, Slimming World and Weight Watchers;
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of these providers are potentially suitable and their
interventions have been described elsewhere [16]. In
brief, each provides goal setting for weight, regular
monitoring, and a tailored energy restriction using a
either a food points system (Weight Watchers), food
portion measures (Rosemary Conley), or controlled
amounts of high energy foods and personal eating plans
(Slimming World).
For this trial, we are using Slimming World, since this
provider has been successful at improving health and
reducing health risks associated with specific medical
conditions through referral schemes within particular
patient populations, some of which are designed to prevent
excessive weight gain rather than focus on weight loss, for
example during pregnancy [22,23]. Such an approach is
particularly pertinent to quitting smokers who need
to prevent cessation-related weight gain.
In addition to usual care, participants will be given a
referral form for Slimming World when they attend their
pre-quit visit. The stop smoking advisor will discuss
times and locations of local group meetings, and attendance
at a convenient group will be agreed. The participant will
attend weight management sessions from their quit day (or
as near to that date as possible). They will attend Slimming
World for 12 weeks receiving support to lose weight
or prevent weight gain. The choice of modest weight
loss or weight gain prevention will depend upon
whether a participant wants to lose weight or not,
and whether or not the participant is overweight or
obese at baseline.
Typically, Slimming World members lose 0.3 kg/week
(or 0.4 kg/week in people who complete 10 of the 12
weeks) [24]. We know that on average 0.2 kg/week is
gained with smoking during the first 12 weeks of quitting
[10]. Factoring in this expected change in weight resulting
from quitting, we would expect a mean weight loss of 0.2
kg/week. For participants who are overweight, a theoretical
minimum weight loss goal may therefore be 2.4 kg or 3/4
stone over 12 weeks, although trials to date to prevent
smoking cessation weight gain have not achieved as
much as this (Table 1). Slimming World consultants
typically agree weight loss targets with their members
at the first appointment, so appropriate targets will
be negotiated on an individual level within realistic
margins. Slimming World consultants then work with
their members to achieve this.
For participants whose starting BMI is 23 kg/m2,
for example a 60 kg woman with a height of 1.62 m,
the weight loss of 2.4 kg described above would
result in a BMI of no less than 22 kg/m2, which is in
the optimum range for longevity; this is why we have
chosen a BMI less than 23 kg/m2 for our exclusion
criteria.Most people attending Slimming World do so with
weight loss as their goal. For participants in this study
who are only seeking to prevent further weight gain,
they will be reassured that weight maintenance (+/−0.5
kg over 12 weeks (see section on sample size)) is an
equally worthwhile target during smoking cessation and
the participant information sheets for the trial will
clearly explain this.
Control
Participants are encouraged to quit smoking first,
before tackling weight. Stop smoking advisors can
advise satiating hunger with healthy foods, but they
will not provide detailed or personalized advice on
weight and will not set weight targets.
Outcome measures
Primary outcome measure
Change in weight from baseline to 12 weeks post-quit
day in abstinent smokers. Abstinence is prolonged
abstinence, defined according to the Russell Standard
as self-report of no more than five cigarettes since 2
weeks following quit day and expired CO less than
10 ppm [21]. Portable validated scales will be pro-
vided to participating Stop Smoking Services. Training
in measurement procedures and the trial protocol will
be provided for all advisors. The same scales will be
used at each clinic at all time points. All measures
will be recorded on paper case report forms (CRFs)
and later entered into a trial database.
Secondary outcome measures
 Weight at 4 weeks post-quit date.
 Weight at 6 months from baseline.
 Abstinence at 4, 12 and 26 weeks. Abstinence will
be defined as not smoking more than five cigarettes
since 2 weeks after the quit day verified by expired
CO <10 ppm at these visits (Russell Standard
criteria). Abstinence will be recorded on the CRF
and in the trials database.
 Participant acceptability.
Participant acceptability
Participant acceptability will be measured quantitatively
by response, attrition rates and a questionnaire as
described below:
 Rates of response to verbal invitation to take part by
stop smoking advisors, including reasons for
declining to participate.
 Rates of attendance at the commercial weight
management meetings by participants randomized
to this intervention.
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intervention compared to usual care.
 Rates of attendance at Stop Smoking Services for
follow-up at 12 and 26 weeks.
 The above measures of acceptability according to
starting BMI; for example are participants who are
obese or overweight more accepting of the
intervention which refers to Slimming World than
those of a healthy weight?
 A questionnaire will be given to participants who
decline to take a part, which will ask them to
provide their age, gender, ethnicity, weight status,
and reason(s) for declining using a series of closed
answer responses (for example: ‘I do not want to
take part in research’, ‘I do not think the intervention
will work’, ‘I do not want to lose weight’) and one
open ‘other’ category.
 All participants who drop out of treatment or
follow-up will be asked, if they are willing, the
reason for discontinuing using a series of closed
answer responses (for example: ‘it was too hard to
quit smoking’, ‘it was too hard to lose weight’, ‘I did
not like the allocation I received’) and one open
‘other’ category.
Feasibility
Feasibility of running the trial within the Stop Smoking
Services will be assessed by questionnaire. Participating
services will be asked to rate the ease of adhering to the
research procedures and describing any difficulties
encountered, such as problems with recording data.
Exploratory outcomes measures
 Self-reported incidence of diabetes.
 Change in EQ-5D.
 Cigarette withdrawal symptom scores as measured by
the mood and physical symptoms scale (MPSS) [25].
 Associations of change in religious engagement
(adapted from CSI-MEMO [26]) and religious
coping (religious coping index (RCI) [27]) at
baseline, and their change over time with tobacco
withdrawal, quitting success and weight
maintenance outcomes.
A recent systematic review of observational studies shows
less smoking is associated with religion. Also, despite a
higher BMI, religious involvement is associated with better
physical and psychological outcomes [28]. The use of
religion as a means to cope with health problems is a
potential mechanism behind this association [27].
Clinical trials comparing weight loss interventions
with a religious element to those without have shown
increased physical activity [29], improved dietary quality[30] and greater mean weight loss [31,32] in participants
receiving the additional religious element. Survey and
qualitative data suggest smokers [33] and those who
overeat [34] are receptive to incorporating a spiritual
element into treatment programmes.
Although this evidence suggests a beneficial association
and an openness to addressing spiritual needs in those
who need to lose weight and stop smoking, many of
these studies have been carried out in the Bible Belt,
USA, and their applicability to the UK population
needs to be determined.
Statistics and data analysis
Sample size
A meta-analysis of studies shows that smokers who
achieve 12 weeks of abstinence gain around 2.5 kg
(SD = 2.5) [10]. A Cochrane review to prevent weight
gain when people stop smoking [15] showed that at 4
and 52 weeks post-quit there was a difference of 1.1
kg and 2.6 kg, respectively, between usual care and
individualized dietary intervention (Table 1). This
means that individualized dietary interventions prevented
most of the expected weight gain at 4 weeks post-quit and
half of it at 1 year post-quit. A realistic estimate is
therefore that we may be able to prevent 80% (2 kg)
of the expected weight gain at 12 weeks post-quit,
that is the intervention group might gain only 0.5 kg
on average. This would require about 32 participants
per arm, 64 participants in total, with an alpha error
rate of 5% and 90% power. Most smokers who attempt
abstinence will relapse to smoking, probably lose any
weight gained [9,31] and will not be included in the pri-
mary outcome assessment. Considering that approximately
only 20% will remain abstinent at 12 weeks, we will need
to randomize 160 participants in each trial arm and 320
participants overall.
Analysis plan
Primary analysis
Change in weight between intervention and the control
arm of the study will be compared using a t-test and
then adjusted for known predictors of weight gain after
cessation, including stop-smoking medication use, using
linear regression analysis. Weight will be analysed in long-
term abstainers because only long-term abstainers gain
more weight over time than the rest of the population.
Secondary analysis
Abstinence will be analysed on an intention-to-treat
basis. This phase II trial is underpowered to detect the
difference between abstinence rates in the control and
intervention arm. We will calculate the proportion of
participants abstinent in each trial arm. Analysis of
abstinence rates will assume participants who do not
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standard practice. Quantitative measures of acceptability
will be presented as descriptive statistics.
Exploratory outcomes
The association of exploratory outcomes with weight
control and quitting success will be examined using
regression modeling and on an intention-to-treat basis.
We will calculate cost of intervention, but will not carry
out any specific health economic modeling in this phase
II trial, since it would be premature to do so. We need
first to establish whether this weight management can
prevent weight gain, before assessing the combined
effects of the weight gain prevented and the effects
on cessation rates in a phase III trial.
Loss to follow-up
In accordance with the Russell Standard, we will
conduct an intention-to-treat analysis and assume
participants lost to follow-up are smokers. We will
attempt to contact participants who do not attend.
Reminder phone calls will also be made before 12-week
and 6-month follow-up appointments.
Trial closure
The end of the trial will be the date of the last follow-up
of the last participant. Six-month follow-up is contingent
upon data at 12-week follow-up.
Study procedures
Training
Stop smoking advisors will be trained in the research
procedures for this study, in line with Good Clinical
Practice (GCP) principles. Training will include how to
screen participants, explain randomization, obtain consent
and document data. Stop smoking advisors will be given
the opportunity to practice via role play and will be
observed doing so. In addition, stop smoking advisors will
be provided with a ‘script’ and a prompt sheet for data
recording for consultations that are beyond usual care.
In the case of any uncertainty (regarding suitability for
inclusion), advisors will be able to contact the research
team for clarification.
Data handling, quality assurance, record keeping and
retention
Data management will be undertaken according with the
standard operating procedures (SOPs) of the Primary Care
Clinical Research and Trials Unit (PC-CRTU) at the
University of Birmingham, Edgbaston, UK. The PC-CRTU
is fully compliant with the Data Protection Act 1998 and
the International Conference on Harmonisation Good
Clinical Practice (ICH GCP). The trial will be registered
with the Data Protection Act website at the University ofBirmingham. Participant identifiable data will be shared
only within the clinical team on a need-to-know basis to
provide clinical care, and to ensure good and appropriate
follow-up. Patient identifiable data may also be shared
with approved auditors from the research ethics commit-
tee (REC), the general practitioner, and NHS Research and
Development (R&D). Otherwise, confidentiality will be
maintained and no one outside the clinical or trial team
will have access to either the case report forms or the
database. On completion of the trial, data will be trans-
ferred to Modern Records, a secure archiving facility at
the University of Birmingham, where they will be held for
a minimum of 10 years and then destroyed.
Case report forms (CRFs)
Data will be collected on a paper CRF and later entered
into an anonymized database for analysis at the University
of Birmingham. The database will contain agreed data
codes, for example for missing data.
Risk assessment
Healthy dietary and lifestyle advice will be individually
tailored to create a mild energy deficit and gentle increase
in activity. This advice will be given by appropriately
trained Slimming World consultants. It is usual practice
and considered very safe. Participants will be given
the contact details of the trial team to report and
discuss any concerns.
Monitoring at study site
The principal investigator will assess adherence to the
trial protocol through observation in clinics, for example
to check advisors are not coercing smokers to take part,
check the implications of randomization are adequately
explained and to check the correct randomization
procedure is followed. Record keeping will also be moni-
tored, for example recording of weights and exhaled CO
readings with random checks of the CRFs. Exhaled CO
readings and participant existence will be verified by
comparison to the source documents, that is stop smoking
advisors records. Any deviations will be recorded, discussed
with the stop smoking advisor concerned and corrected
either immediately or at following clinics. The trial is
potentially subject to audit by the appropriate regulatory
authorities and monitoring by the lead Comprehensive
Clinical Research Network, and therefore participants will
be asked to provide consent to allow their records to be
viewed by these authorities.
Ethics approval
The study co-ordination centre has obtained approval
from the Cornwall and Plymouth Research Ethics
Committee. The trial will be conducted in accordance
with the recommendations for physicians involved in
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Medical Assembly, Helsinki, 1964, and later revisions.
Participant consent
The process for obtaining participant informed consent
will be in accordance with GCP. The stop smoking
advisor and the participant shall both sign and date the
consent form before any trial procedures begin. A copy
of the signed form will be kept by the participant and
the original will be retained at the trial site. A second
copy will be forwarded to the general practitioner to file in
the participant’s medical notes. The participant’s decision
to take part in the trial is entirely voluntary. It will be
explained to potential participants that they can withdraw
consent at any time without penalty or affecting the quality
or quantity of their future medical care.
Participants will be informed of any relevant infor-
mation that becomes available that affects their
participation in the study. Revised consent forms will
be used if applicable and amended forms will be
submitted to the main REC for favourable opinion
prior to use. Revised informed consent forms will be
signed by the parties specified above.
Confidentiality
Participants’ identification data will be required for the
registration process. The study co-ordination centre will
preserve the confidentiality of participants taking part in
the trial and is registered under the Data Protection Act
1998. Consent will be sought from patients for members
of the study team, regulatory authorities and the relevant
health provider to access patient medical records.
Indemnity
The University of Birmingham holds public liability
(negligent harm) and clinical trial (non-negligent harm)
insurance policies, which apply to this trial.
Sponsor
The University of Birmingham will act as the sponsor
for this trial.
Funding
Pump priming funds from the UK Centre for Tobacco
Control Studies (UKCTCS) are funding this trial and the
National Institute for Health Research School for Primary
Care Research (NIHR-SPCR) paid the fellowship of the
chief investigator while at the University of Birmingham.
Audits
The trial may be subject to inspection and audit by The
University of Birmingham, under their remit as sponsor,
the study co-ordination centre and other relevant bodies,
for example National Research Ethics Service.Participant payments
Participants will receive payment for travel and
inconvenience at the following visits:
 12-week follow-up: £5 voucher.
 6-month follow-up: £5 voucher.
 Payments to NHS Stop Smoking Service.
The NHS Stop Smoking Service will be reimbursed for
their time as appropriate from service support funding,
for example to obtain participant consent.
Treatment costs
Excess treatment costs of a 12-week membership at
Slimming World will be provided to the trial free of charge
in the form of vouchers by Slimming World.
Discussion
This trial will establish whether referral to the 12-week
Slimming World programme plus usual care is an effective
intervention to prevent cessation-related weight gain. If so,
we will seek to establish whether weight control
comes at the expense of a successful quit attempt in
a further non-inferiority trial.
Positive results from both these trials would provide a
potential solution to cessation-related weight gain, which
could be rolled out across England within Stop Smoking
Services to better meet the needs of 0.75 million
smokers stopping with NHS support every year.
Trial status
Participant recruitment began in October 2012.
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